Australia's Rhinomed rises on positive clinical trial results

Rhinomed

21/12/2021 02:46

** Shares of medical device maker Rhinomed Ltd  RNO.AX  rise
as much as 11.3% to A$0.295, set for their best day since Dec. 1
    ** Co completes clinical trial of Rhinoswab Junior, which is
designed to collect a nasal sample from children for diagnosis
of respiratory virus, at Murdoch Children's Research Institute
of Melbourne Children Trials Centre  urn:newsml:reuters.com:*:nASX7nMHhM
    ** Says Rhinoswab Junior met its primary efficacy endpoint
in the trial
    ** Says in the current climate, Rhinoswab Junior detected
100% of the patients with SARS-CoV-2
    ** Shares hit their highest since Dec. 3
    ** As of last close, stock up 65.6% this year 

 (Reporting by Himanshi Akhand in Bengaluru)
 ((Himanshi.Akhand@thomsonreuters.com;))